ArticleScientific reports2026
LOC100912399 regulates osteogenic differentiation of bone marrow mesenchymal stem cells through modulating p38MAPK signaling-mediated oxidative stress and apoptosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aims to investigate the role and underlying mechanism of the long non-coding RNA (lncRNA) LOC100912399 in regulating osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), with a specific focus on its involvement in oxidative stress-induced apoptosis via the p38 mitogen-activated protein kinase (p38MAPK) signaling pathway. BMSCs were isolated from the tibiae and fibulae of Sprague-Dawley (SD) rat pups and cultured to the third passage. Cell purity was confirmed by flow cytometric analysis of surface markers (CD45, CD29, CD106, CD90, CD11b), and multilineage differentiation potential was verified using Alizarin Red S (osteogenic), Oil Red O (adipogenic), and Alcian Blue (chondrogenic) staining. At 90% confluence, BMSCs were transduced with lentiviral vectors for LOC100912399 overexpression (Lv-LOC100912399) or knockdown (Sh-LOC100912399), alone or in combination with p38MAPK pathway inhibition or overexpression (Lv-p38MAPK), followed by exposure to oxidative stress for 48 h. Apoptosis was evaluated by Annexin V/PI staining, cell viability by CCK-8 assay, and gene expression by quantitative real-time PCR (qRT-PCR). Protein levels of oxidative stress-related enzymes (MnSOD, CAT, GPx), apoptosis-related factors (Bcl-2, Bax, p-p38MAPK), and osteogenic markers (RUNX2, OPN, ALP) were determined by Western blot. High-purity BMSCs (> 99%) were successfully isolated and characterized. Overexpression of LOC100912399 significantly promoted oxidative stress-induced apoptosis, reduced cell viability, downregulated antioxidant enzyme expression, increased the Bax/Bcl-2 ratio, and inhibited osteogenic differentiation (P < 0.05). Conversely, knockdown of LOC100912399 enhanced antioxidant capacity, suppressed apoptosis, and upregulated osteogenic marker expression (P < 0.05). These effects were further modulated by either p38MAPK overexpression or inhibition, indicating that LOC100912399 functions, at least in part, through the p38MAPK signaling pathway. LOC100912399 regulates oxidative stress and apoptosis in BMSCs via the p38MAPK signaling pathway, thereby influencing osteogenic differentiation. Targeting LOC100912399 may represent a potential therapeutic strategy for enhancing bone formation under oxidative stress-related conditions such as osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.